Literature DB >> 10078747

Pramipexole in progressive supranuclear palsy.

W J Weiner1, A Minagar, L M Shulman.   

Abstract

Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder with no effective treatment. Dopaminergic agents occasionally produce transient symptomatic improvement. The authors report the results of pramipexole treatment (4.5 mg daily) in six patients with PSP (average disease duration, 4.4 years). Patients were treated for 2 months. Patients were evaluated with the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr stage, and Schwab and England Activities of Daily Living Scale at baseline and 2 months. Pramipexole was not efficacious for the symptoms of PSP.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10078747     DOI： 10.1212/wnl.52.4.873

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

Review 1.  Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report.

Authors:  Deborah A Hall; Maria João Forjaz; Lawrence I Golbe; Irene Litvan; Christine Ann M Payan; Christopher G Goetz; Albert F G Leentjens; Pablo Martinez-Martin; Anne Pavy-Le Traon; Cristina Sampaio; Bart Post; Glenn Stebbins; Daniel Weintraub; Anette Schrag
Journal:  Mov Disord Clin Pract       Date:  2015-05-22

Review 2.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

4.  Progressive Supranuclear Palsy.

Authors:  Lawrence I. Golbe
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 5.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 6.  Four-Repeat Tauopathies: Current Management and Future Treatments.

Authors:  Lawren VandeVrede; Peter A Ljubenkov; Julio C Rojas; Ariane E Welch; Adam L Boxer
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 7.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.